TGFB1 and Hepatic fibrosis: Also, treatment for a period of two years is well-tolerated and increasing time of treatment renders enhanced benefits as observed in this HCV-liver fibrosis patient cohort, i.e. recovering in hepatic markers, TGF-β1 and pro-inflammatory cytokines serum levels reduction as well as, mRNA levels of CB2 mRNA increase.